BIOMAT Database Logo BIOMAT Database Logo

Letter: Myeloma cells after treatment with alkylating agents. 1975

M Baccarani, and A Santucci

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000477 Alkylating Agents Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. Alkylating Agent,Alkylator,Alkylators,Agent, Alkylating,Agents, Alkylating

Related Publications

M Baccarani, and A Santucci
Letter: Alkylating agents and myeloma cells.
June 1976, Blood,
M Baccarani, and A Santucci
Letter: Androgen role in erythroleukemia after treatment with alkylating agents.
July 1974, Annals of internal medicine,
M Baccarani, and A Santucci
Salvage treatment for patient with multiple myeloma refractory to alkylating agents.
January 1985, Medical and pediatric oncology,
M Baccarani, and A Santucci
Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
January 1978, Acta medica Scandinavica,
M Baccarani, and A Santucci
Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
July 2008, Leukemia research,
M Baccarani, and A Santucci
Effective treatment of advanced multiple myeloma refractory to alkylating agents.
May 1984, The New England journal of medicine,
M Baccarani, and A Santucci
Ovarian reserve after treatment with alkylating agents during childhood.
June 2015, Human reproduction (Oxford, England),
M Baccarani, and A Santucci
Leukemia after treatment of ovarian cancer with alkylating agents.
June 1983, The New England journal of medicine,
M Baccarani, and A Santucci
Multiple myeloma and acute leukemia associated with alkylating agents.
January 1975, Archives of internal medicine,
M Baccarani, and A Santucci
Alkylating agents as leukemogens in multiple myeloma.
April 1974, Cancer,
Copied contents to your clipboard!